Kezar Life Sciences has become the latest biotech to decide that it could do better than a buyout offer from Concentra Biosciences.

Sage Therapeutics’ latest attempt to shrink its pipeline and workforce will see a third of the biotech’s employees heading for the exits along with a swath of the company’s leadership.

Johnson & Johnson is jettisoning several programs, with three of the culls taking place in the neuroscience field.

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk’s Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) and body weight in a phase 2 trial in patients with type 2 diabetes, the company announced in an Oct. 15 release.

MeiraGTx is looking to march its Parkinson’s disease treatment forward into phase 3 after the gene therapy improved motor ability and quality of life in a small midphase trial.

Panthera Biopartners is roaring with pride after becoming the first British clinical trial organization to join Parexel’s Site Alliance Vaccine Network.

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials.

Abbott has received an FDA clearance for the latest version of its sensor-laden catheter used to map out the electrical activity of the heart muscle—a device the company says will help support its upcoming ablation devices for treating atrial fibrillation, each of which are making their own progress in clinical studies.

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it failed to meet its primary and secondary endpoints, dealing a further blow to a collaboration with a troubled history.

Difficult. Impossible. Agonizing. Worse than voting in the national election. All those descriptors were used today by FDA advisory committee members when asked to vote on an investigational rare disease therapy.